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86 The Journal of Thoracic and Cardiobjectives: Unfractionated heparin has many shortcomings, including indirect and
artial inhibition of thrombin, antibody formation, and platelet activation. Bivalirudin,
short-acting direct thrombin inhibitor, avoids these limitations and has superior
utcomes during percutaneous revascularization. This trial was performed to evaluate
he safety and efficacy of bivalirudin in off-pump coronary artery bypass grafting.
ethods: An open-label, multicenter randomized trial compared heparin with prota-
ine reversal to bivalirudin in patients undergoing off-pump coronary artery bypass.
he primary objective was safety as demonstrated by similar rates of procedural success
efined as freedom from a composite of death, myocardial infarction, stroke, and
epeat revascularization. Twenty-one institutions randomized 105 patients to receive
ivalirudin and 52 patients to receive heparin.
esults: The mean age was 65 years for both groups. The bivalirudin group had
ore grafts: 3.0  1 versus 2.5  1. Procedural success rates at 30 days were
dentical in bivalirudin- and heparin-treated patients (93%). Operative times, total
lood loss, reoperations for bleeding, and major adverse events were not signifi-
antly different. Strokes were more frequent in the heparin group: 5.5% versus 0;
 .05. Mortality was 2% in each group. Repeat revascularization was required in
% of bivalirudin- and 2% of the heparin-treated patients.
onclusions: For patients undergoing off-pump coronary artery bypass grafting,
ivalirudin was an effective anticoagulant, without excessive bleeding and with a
afety profile similar to that of heparin. Further trials are warranted to assess whether
nticoagulation with bivalirudin improves clinical outcomes.
he phenomenal growth and outstanding results of surgical and percutaneous
vascular procedures attest to the utility of heparin, but limitations of this
agent include incomplete anticoagulation, heparin resistance, and the in-
reasingly relevant development of heparin antibodies. Bivalirudin, a reversible
irect thrombin inhibitor with a short half-life, is an intriguing alternative to heparin
nd has properties that may improve outcomes.
Investigation of the utility of bivalirudin in cardiac surgery has followed clinical
uccess with the drug in percutaneous interventions,1 off-pump coronary bypass
rafting (OPCAB), and off-label use of the drug for patients with heparin-induced
hrombocytopenia (HIT).1-3 In the REPLACE-2 trial of percutaneous coronary
ntervention, bivalirudin was statistically not inferior to heparin plus platelet gly-
oprotein IIb/IIIa blockade in reducing ischemic events and was associated with less
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ETleeding.1 Merry and colleagues4 assessed the efficacy of
ivalirudin in a 100-patient, randomized single institution
PCAB trial. Bivalirudin showed a safety profile similar to
hat of heparin with improved thrombolysis in myocardial
nfarction (TIMI) flow. An editorial5 accompanying the
ublication by Merry and associates outlined the drug’s
otential advantages, including inhibition of clot-bound
hrombin, slow reversal of anticoagulation, and possibly a
educed risk of developing HIT—a known risk factor for
erioperative thrombotic complications.
The EVOLUTION (EValuation of Patients during coro-
ary artery bypass graft Operations: Linking UTilization of
ivalirudin to Improved Outcomes and New anticoagulant
trategies) trial is the first open-label multicenter controlled
valuation of a new anticoagulant as a potential alternative
o heparin in patients undergoing OPCAB.
atients and Methods
tudy Design
his was an open-label study sponsored by the Medicines Company
Parsippany, NJ). Patients scheduled for elective OPCAB were ran-
omized in a 2:1 ratio to bivalirudin or heparin. Excluded were
atients with HIT (evaluated in a separate nonrandomized protocol),
revious sternotomy, on dialysis, stroke within 6 months, those re-
eiving warfarin, clopidogrel (within the prior 5 days), lepirudin, or
gatroban (within the prior 24 hours), or with a known allergy to
ivalirudin or hirudin-type drugs.
The primary objective was to assess the safety of bivalirudin as
efined by the end points of death, Q-wave myocardial infarction
MI), repeat coronary revascularization and stroke (hemorrhagic
nd ischemic) at 7 days/discharge (primary end point), and at
0 days and 12 weeks (secondary end points). Non–Q-wave MI,
leeding outcomes, and other safety variables were also evaluated.
efinition of Variables
Abbreviations and Acronyms
ACT  activated clotting time
CABG  coronary artery bypass grafting
EVOLUTION EValuation of Patients during
coronary artery bypass graft
Operations: Linking UTilization of
bivalirudin to Improved Outcomes
and New anticoagulant strategies
HIT  heparin-induced thrombocytopenia
MI myocardial infarction
OPCAB  off-pump coronary artery bypass
grafting
REPLACE  Randomized Evaluation in PCI
Linking Angiomax to Reduced
Clinical Events
TIMI  thrombolysis in myocardial infarctionDeath. All-cause through 12 weeks. d
The Journal of ThoracicQ-wave MI. New Q wave of more than 0.04 milliseconds’
uration or a depth greater than one fourth of the corresponding
-wave amplitude, or both, in 2 contiguous leads.
Non–Q-wave MI. Creatine kinase MB elevation of 10 times
he upper limit of normal or greater and, after 24 hours, by creatine
inase MB greater than the upper limit of normal on 2 successive
amples or greater than 2 times the upper limit on 1 occasion with
vidence of ischemic symptoms or electrocardiographic changes
f ischemia.
Incomplete revascularization. A vessel originally targeted for
evascularization was not grafted.
Repeat coronary revascularization. Percutaneous or repeat
urgical revascularization after OPCAB.
Stroke. Any cerebrovascular accident, ischemic or hemor-
hagic, as recognized by change in neurologic status lasting at least
4 hours or leading to death.
Procedural success was defined by absence of death, Q-wave
I, repeat revascularization, or stroke at 7 days or discharge, at
0 days, and again at 12 weeks. Bleeding was analyzed separately.
olume of chest tube drainage, quantity of transfusions, and
e-exploration for bleeding were examined. Major bleeding events
ere defined as intracranial, intraocular, retroperitoneal, or gastro-
ntestinal bleeding that occurred within 7 days.
tatistical Method
he sample size was not powered to test a formal statistical
ypothesis. Complications were analyzed by both the intention-
o-treat population and the safety population (all patients who
eceived drug, categorized by treatment received). No differences
ere found and results are presented for the safety population.
escriptive statistics were used to summarize most of the data.
uantitative (continuous) variables were summarized by mean,
tandard deviation, median, and interquartile ranges. Qualitative
categorical) variables were summarized by frequencies and per-
entages. Because of the small number of patients, exploratory
onparametric tests (Fisher exact test for categorical variables,
ilcoxon rank-sum test for continuous variables) were used to
alculate P values. The raw data were supplied to the Cleveland
linic Foundation for independent statistical analysis. There were
o restrictions placed by the sponsor of the trial on publications or
resentation of the trial’s results.
atients
total of 157 patients were randomized at 21 centers. Of the 105
atients randomized to bivalirudin, 4 patients received only hep-
rin because of surgeon preference (n  1), necessity of valve
ntervention (n  1), and exclusion criteria identified after ran-
omization (n  2). Two additional patients randomized and
eceiving bivalirudin required conversion to cardiopulmonary by-
ass; one received heparin and the other continued to receive
ivalirudin. Of the 56 patients who received heparin (52 random-
zed  4 as described above), 2 were converted to cardiopulmo-
ary bypass and 1 was selected for valve intervention. The safety
opulation, therefore, consisted of 101 patients receiving bivaliru-
in and 56 receiving heparin.
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ETntraoperative Management
PCAB technique was at the discretion of the surgeon. Centers
ere advised to avoid static columns of blood because of the
etabolism of bivalirudin by thrombin, which could lead to local
eduction in anticoagulation. Aprotinin (Trasylol; Bayer, Mann-
eim, Germany) or aminocaproic acid (Amicar; Wyeth, Madison,
J) were used in 48% of the bivalirudin- and 30% of the heparin-
reated patients.
Bivalirudin was given as a 0.75 mg/kg intravenous bolus and a
.75 mg · kg1 · h1 infusion for the duration of the procedure,
ith the option to increase or decrease the infusion in 0.25 mg ·
g1 · h1 increments or administer additional 0.1 to 0.5 mg/kg
oluses to maintain an activated clotting time (ACT) greater than
00 seconds. Maintenance infusion was discontinued at the dis-
retion of the cardiac surgeon and anesthesiologist, but was com-
only stopped 15 minutes before flow would be restored down all
rafts. Heparin was administered on a weight-adjusted basis to
each an ACT greater than 300 seconds. Protamine was given in all
eparin-treated patients at a mean dose of 205 mg (range 15-450 mg);
4 patients received 100 mg or less of protamine.
esults
aseline patient characteristics were similar (Table 1). The
ajority of patients received at least one internal thoracic
rtery graft. In the heparin group, significantly fewer bypass
rafts were performed with a slightly higher rate of incom-
lete revascularization; nevertheless, the duration of the
rocedure was similar (Table 2). Composite and individual
nd points at 7 days/discharge, 30 days, and 12 weeks
ccurred infrequently and their rates were not significantly
ifferent (Table 3). Three strokes occurred, all in the hep-
rin arm, representing a statistically significant difference
etween treatment groups (5.5% vs 0%; P  .05). All were
schemic and occurred at 3 and 7 days after the OPCAB.
epeat revascularization was required in 4 patients. One
eparin-treated patient underwent repeat coronary artery
ypass grafting (CABG) and thrombus was found in a vein
raft to the distal right coronary artery. In the bivalirudin









(Q1, Q3) (56, 73) (60, 73)
ale, n (%) 77 (76.2) 45 (80.4)
edical history, n (%)
History of MI 37 (36.6) 24 (42.9)
Prior PCI procedure 25 (24.8) 18 (32.1)
Congestive heart failure 13 (12.9) 5 (8.9)
Diabetes 31 (30.7) 18 (32.1)
I, Myocardial infarction; PCI, percutaneous coronary intervention. All
 not significant.rm, 3 patients underwent percutaneous revascularization of q
88 The Journal of Thoracic and Cardiovascular Surgery ● Marceft internal thoracic artery grafts to the left anterior de-
cending artery, which were occluded at 2, 42, and 44 days
fter operation. Rates of Q-wave and non–Q-wave MI were
imilar between groups. All-cause mortality was low (2%)
nd identical between groups at 30 days and 12 weeks.
Bleeding complications and use of transfusion occurred
t similar rates (Table 4, Figure 1). For patients who re-
eived a transfusion, those treated with bivalirudin received
ignificantly more units of packed red blood cells (4.0 vs
.3). Reoperation for bleeding was similar: bivalirudin 7.9%
ersus 5.4% for heparin. Although more aminocaproic acid
nd aprotinin was used in the bivalirudin arm, this use and
he degree of heparin reversal with protamine did not affect
he rates of bleeding, transfusion, or end points.
iscussion
his study was designed to assess the safety of bivalirudin
n patients undergoing OPCAB in the general cardiac sur-
ical community. In this setting, bivalirudin resulted in
imilar rates of major adverse events and bleeding at 7
ays/discharge, 30 days, and 12 weeks when compared with
eparin. OPCAB was initially studied to minimize the com-
lexities of managing a new drug in both the operative field
nd bypass circuit.
Bivalirudin is a 20 amino acid synthetic peptide that
irectly inhibits thrombin and has a short half-life. For
nticoagulants to work effectively and safely during cardiac
urgery, they must have a rapid onset of action, maintain a
esired level of anticoagulation, and allow hemostasis once
iscontinued. Previous off-2,4 and on-pump3 series have
uggested that bivalirudin fulfills all these requirements, and
his was confirmed in this study.
Hemorrhagic complications occurred with equal fre-






uration of operation (min)
Median 189 192
(Q1, Q3) (150, 238) (141, 236)
o of grafts
Mean  SD 3.0 1.0 2.5 0.9*
ype of graft, n (%)
LITA 98 (97.0) 52 (92.9)
RITA 4 (4.0) 2 (3.6)
Saphenous vein 88 (87.1) 43 (76.8)
Radial artery 22 (21.8) 10 (17.9)
ncomplete revascularization, n (%) 4 (4.0) 5 (8.9)
se of aminocaproic acid or
aprotinin, n (%)
48 (47.5) 18 (32.1)
ABG, Coronary artery bypass grafting; SD, standard deviation; LITA, left
nternal thoracic artery; RITA, right internal thoracic artery. *P  .003; all
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ETerry’s bivalirudin group and similar to published data for
PCAB.4 The reoperation rates of 7 % in the bivalirudin
roup and 6% in the heparin arm are higher than expected
or OPCAB, and although more heparin patients were trans-
used, bivalirudin patients received more packed cells per
ransfusion episode. The vast majority of published reop-
ration rates are less than 3% although the reoperation rate
n one series was 4% when patients having circumflex grafts
r acute MIs were included.7,8 The indication and threshold
or reoperation for bleeding was not defined in the protocol,
nd this higher rate of reoperation is unlikely a lower
olerance for bleeding since the median blood loss in the
atients taken back for bleeding exceeded that of those not
aken back by almost 2 L. We could not find an obvious
xplanation for the high reoperation rates. Case clustering,
se or nonuse of aminocaproic acid or aprotinin, incomplete
eversal of heparin with protamine, and high intraoperative
CT in the bivalirudin group were not associated with
leeding. The possibility remains that the high rates of
eoperation and need for transfusions in the heparin arm
asked excessive bleeding in the bivalirudin group.
OPCAB has been associated with better myocardial pro-
ection as manifested by uniformly low creatine kinase
elease. Van Dijk and colleagues,6 in a randomized trial of
PCAB compared with on-pump CABG, showed creatine
inase MB release was significantly lower at all time points
rom 2 to 20 hours after surgery in the OPCAB group.
ABLE 3. Summary of efficacy end points
Day 7/discharge
Bivalirudin Heparin B
rimary and secondary efficacy end points
rocedural success
N 101 56
n (%) 97 (96.0) 53 (94.6) 9
on–Q-wave MI
N 101 56
n (%) 4 (4.0) 3 (5.4)
linical end points included in the composite end point procedura
eath
N 101 56
n (%) 1 (1.0) 1 (1.8)
-wave MI
N 101 56
n (%) 2 (2.0) 0 (0.0)
epeat revascularization
N 101 56
n (%) 1 (1.0) 1 (1.8)
troke
N 101 56
n (%) 0 (0.0) 2 (3.6)
I, Myocardial infarction. *P  .05.efinitions of MI have varied in different studies, but in 9
The Journal of Thoraciceneral the rate has been less than 5% for OPCAB.6-9 MIs
n this trial occurred at rates that were comparable with prior
PCAB series. Almost twice as many bivalirudin patients
eceived aminocaproic acid or aprotinin, but stratifying pa-
ients by use of these drugs did not affect the occurrence of
Is in either group.
The reintervention rate in the bivalirudin arm was 3%,
hich is comparable with published rates.6-9 Loss of 3 left
nternal thoracic arteries to the left anterior descending
rtery in the bivalirudin group is concerning, but the number
f events is too small to determine whether this is related to
hance or possibly to how the conduit was handled or
elated to the drug itself. Theoretically, if the internal tho-
acic artery was detached from the chest wall for any period
f time before flow was re-established through the graft,
hrombus could potentially develop within the graft owing
o metabolism of bivalirudin by thrombin within the stag-
ant blood column. The patency of the bypass grafts was not
ssessed by systematic angiography in this series, and in
ther series graft patency has been quite variable. Many
ave shown outstanding patency rates whereas others have
hown decreased patency when OPCAB is compared with
n-pump grafting. Khan and associates8 recently published
randomized trial of OPCAB versus on-pump CABG in
he New England Journal of Medicine. At 3 months, 82%
f the patients underwent follow-up angiography. Patency
as significantly reduced in the OPCAB group (88% vs
30 days 12 weeks
udin Heparin Bivalirudin Heparin
56 100 56
.0) 52 (92.9) 93 (93.0) 52 (92.9)
55 99 55
0) 3 (5.5) 4 (4.0) 3 (5.5)
cess
56 100 56
0) 1 (1.8) 2 (2.0) 1 (1.8)
55 98 55
0) 0 (0.0) 2 (2.0) 0 (0.0)
56 98 56
1) 1 (1.8) 3 (3.1) 1 (1.8)
55 98 55













0 (0.8% for on-pump). In Merry’s trial,4 79% of patients re-
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6
ETurned for follow-up angiography. The bivalirudin cohort
ad more grafts with normal flow than did the heparin
roup, 82% compared with 67%, and more patients in the
ivalirudin arm had complete flow in all grafts; 60% versus
8%. A larger cohort of patients with follow-up angiogra-
hy would need to be examined to determine whether
ivalirudin affects graft patency.
One potential advantage of OPCAB is avoidance of
ardiopulmonary bypass and aortic crossclamping. Despite
his theoretical advantage, published series, including this
ne, have been too small to determine whether off-pump
urgery actually reduces long-term neurologic event rates.10
here were no strokes in patients receiving bivalirudin, and
he 6% rate in the heparin arm is higher than the expected
ate of around 2% from published series. An interesting
nding is that the strokes occurred 3 or more days after
urgery; whether such late events were related to arrhyth-
ias such as atrial fibrillation or a prothrombotic state





otal blood loss postop (mL)
N 101 55
Median 717 783
(Q1/Q3) (475, 1190) (528, 1032)
Maximum 15405 5610
ransfusion at day 7/discharge
N 101 56
n (%) 46 (45.5) 33 (58.9)
ransfusion product by day 7/
discharge, n (%)
N 101 56
PRBC 42 (41.6) 30 (53.6)
Platelets 13 (12.9) 5 (8.9)










(minimum, maximum) (1.0, 24.2) (2.0, 10.0)
otal units/patient—fresh frozen
plasma by day 7/discharge
N 15 8
Median 3.3 3.0
(minimum, maximum) (1.5, 26.0) (1.0, 6.7)
RBC, Packed red blood cells. *P  .012.nduced by heparin exposure warrants further investigation. m
90 The Journal of Thoracic and Cardiovascular Surgery ● Marcimitations
his was a small pilot using a composite end point to assess
afety. A large number of centers participated, many enroll-
ng fewer than 15 patients, and intraoperative and postop-
rative management was left to the surgeon and center. This
ay have affected results in unpredictable ways, and im-
rovement of these results can be expected with more
xperience. Because of the small number of patients, com-
arison of specific outcomes such as bleeding or strokes
ust be done cautiously and generalizations avoided. With-
ut angiography, graft patency is unknown and any poten-
ial advantage of bivalirudin in this regard remains
heoretical.
This multicenter trial provides further evidence to sug-
est that bivalirudin is a safe and effective alternative to
eparin plus protamine for anticoagulation of patients un-
ergoing OPCAB. Better understanding of the drug kinet-
cs, the best method to monitor anticoagulation, and devel-
ping an effective method to reverse the anticoagulation
ffects without promoting thrombosis will enhance the
afety profile. The efficacy of bivalirudin in on-pump sur-
ery has been assessed in a separate trial. Future large-scale
nvestigations will be necessary to evaluate the potential of
ivalirudin to surpass heparin in regard to procedural suc-
ess and reduction in cardiovascular complications. At the
resent time, bivalirudin has not been approved by the Food
nd Drug Administration for use in cardiac surgery.
We thank Colleen Vahcic, Nadine Juran, RN, and Mark Sum-
ray, MD for their invaluable help in the preparation of this
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ppendix
he following institutions participated in the trial:
Germany: Berlin Heart Center, Berlin, Germany (n  22).
New Zealand: Mercy Hospital/University of Auckland, Auck-
and, New Zealand (n  1).
United States: VCU Health System/Medical College of Vir-
inia, Richmond, Va (n  3); Washington University School of
edicine/Washington University Medical Center, St Louis, Mo
n  3); Comanche County Memorial Hospital, Lawton, Okla
n  7); Enloe Medical Center, Chico, Calif (n  4); Houston
orthwest Medical Center, Houston, Tex (n  38); Florida Heart
nstitute at Florida Hospital, Orlando, Fla (n  10); Baylor Uni-
ersity Medical Center, Dallas, Tex (n  2); Charleston Area
edical Center (CAMC), Charleston, WVa (n  20); Kaiser
ermanente Medical Center, Honolulu, Hawaii (n  5); New
ngland Medical Center, Boston, Mass (n  1); St Michael’s
edical Center, Newark, NJ (n 5); Washington Hospital Center,
ashington, DC (n  3); Sparks Regional Medical Center, Fort
mith, Ark (n 2); Bassett Healthcare, Cooperstown, NY (n 2);
cGuire VA Medical Center, Richmond, Va (n  1); VAMC,
ashington, DC (n  1); Banner Thunderbird Medical Center,
lendale, Ariz (n 4); Nebraska Methodist Hospital, Omaha, Neb r
The Journal of Thoracicn 19); The Cardiopulmonary Research Science and Technology
nstitute (CRSTI), Dallas, Tex (n  4).
iscussion
r John C. Chen (Honolulu, Hawaii). This prospective, open-
abel, multicenter clinical trial aims to compare the safety and
ffectiveness of bivalirudin versus heparin anticoagulation in pa-
ients undergoing CABG. The major potential advantages of the
tudy medication are avoidance of HIT and protamine reactions.
lthough bivalirudin can be used on pump, OPCAB was initially
tudied to minimize the complexities of managing a new drug in
oth the operative field and bypass circuit.
Should studying first in off-pump surgery be a paradigm for
harmacologic CABG trials in the future?
Dr Smedira. It depends on what we are studying. Our idea was
hat the drug’s mechanism of action was so different from that of
eparin that we had to think through how we managed the oper-
tive field. The real concern was that any static columns of blood
ould potentially thrombose if that blood was not replenished with
new source of bivalirudin. Thus, do you disconnect the thoracic
rtery from the chest wall when you walk in the room or do you
eave it intact to allow blood to flow through that? Do you do your
roximal grafts first or your distal grafts? Where do you put the
ulldog clamp? What do you flush with? If we are talking about a
rug that requires a change in how we manage the intraoperative
eld, it may be something worth considering. That said, it turns out
hat the on-pump studies were straightforward to do and the drug
as easy to use. We were very cautious because we thought that
e could handle bleeding but that the loss of grafts or thrombosis
f conduits would have been a major setback.
Dr Chen. This was an intention-to-treat pilot trial of 157
atients at 21 centers using a composite end point to assess safety.
ou chose to study a composite primary end point of death,
-wave MI, repeat coronary revascularization, stroke, and bleed-
ng within 7 days of surgery. Why did you decide on a composite
nd point with so many variables in the initial study design? I do
ot quite see the association between stroke within 7 days of
urgery and the need for later repeat coronary revascularization.
Dr Smedira. One of the issues is that with such a small number
f patients, if you do not define a series of end points you are not
oing to show any difference. We really needed to have a number
f events to see whether we could determine a difference between
he two groups. That is why we used the composite end points.
hat being said, some published data indicate that after exposure
o heparin there is the development of a prothrombotic state,
specially in the off-pump situation. You could argue that the
trokes that we see postoperatively, and other events like loss of
ypass grafts, may be related to a prothrombotic state and the
omposite end points of stroke, and need for revascularization may
ave been diminished by use of drugs that could potentially reduce
hese effects. Those are some theoretical arguments that have been
outed as one of the potential advantages of this drug-that it doesn’t
nduce a prothrombotic state after surgery.
Dr Chen. In the manuscript you noted that, despite signifi-
antly more aminocaproic acid and aprotinin use in the bivalirudin
roup versus the heparin group, transfusion rates were similar
etween the two groups. Do you have any insight as to the
ationale for such a high percentage of antifibrinolytic drug use
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ETmong surgeons performing OPCAB? The percentages were 30%
nd 47%, I believe.
Dr Smedira. No, I don’t know. The approach was left to the
ndividual surgeon or center. It was higher than I would have
xpected and I don’t know the rationale.
Dr Chen. My final question relates to a specific patient treated
ith bivalirudin. The manuscript lists and your slide illustrates a
atient sustaining over 15 L of blood loss. Was this patient
eturned to the operating room for bleeding? If he was, what was
ound?
Dr Smedira. This unfortunate gentleman was in the operating
oom for 6 or 8 hours. From what I understand, they had great
ifficulty with the circumflex coronary artery during grafting, had
lot of bleeding, had to regraft it a number of times, and put a
atch on it. Then they had difficulties with bleeding. He was
eturned to the intensive care unit and then to the operating room
or re-exploration. It sounds like one of those nightmarish cases
hat occasionally occur. We did not think that it was directly
elated to the drug.
Dr Scott Rankin (Nashville, Tenn). Congratulations on an
xcellent study. There has always been a need to approach the HIT
roblem and I think your initial concept is a good one. It is also
ice to see it being explored in a scientific way with randomized
rials on the front end.
My question relates to the vascular occlusive phenomena that
ou see here, specifically potential differences in stroke rates with
he bivaliruden group having a lower stroke rate postoperatively
ut having a higher thoracic artery occlusion rate. Do you think
ith a larger sample size that these phenomena may become
tatistically and clinically significantly different? On the basis of
ore detailed analysis of those specific cases, what do you think
he significance of those phenomena is? For example, looking at
he patients who had cerebrovascular disease preoperatively, was
here any influence there? Examining the thoracic artery occlu-
ions postoperatively, were they from dissections or did it look like
t was a good anastomosis and just an in situ thrombosis? Do you
ave any more information on that?
Dr Smedira. Thank you. Your first question concerned whether,
iven more patients, we could potentially sort out whether the strokes
nd arterial occlusions are a real phenomena. Potentially, I think we
ould. I did look into the operative details on the occlusions and, from
hat I could discern from the intraoperative management and what
as done and seen, it seemed like it was a straightforward case. There
as no concern about the anastomosis, no concern about the flow or
he integrity of the thoracic artery, and yet 3 were occluded within
bout 6 weeks. I wondered whether taking the thoracic artery down
arly and placing a bulldog clamp distally might have predisposed
o the development of thrombosis within the wall. I think that is
efinitely a possibility. As a result, when I use the thoracic artery
ff-pump or even on-pump, I leave it in situ on the wall until right
efore I’m going to use it. t
92 The Journal of Thoracic and Cardiovascular Surgery ● MarcAs for the strokes, it is so hard to tell. The study only looked at
he occurrence of a neurologic event. It did not really go into great
etail about the stroke. As I mentioned, one patient had to go on
ypass urgently because of hypotension and was identified as
aving a stroke on day 3. They were not hemorrhagic, and we do
ot have a lot of details on the other two, so I do not know if that
s a thrombotic issue related to heparin exposure and potential
ntibody formation or simply something like atrial fibrillation.
Dr Robert Guyton (Atlanta, Ga). I think it is a very important
opic. Like others, we are using this when we need to in the
PCAB patients. My concern is similar to Dr Rankin’s in that not
nly were there 3 occlusions but there was a 9% MI rate in the
ivalirudin group. Are there data either from subparts of this
eries, institutions that did postoperative catheterization or from
lsewhere, about graft patency in patients who have had bivaliru-
in. We have long been advocates of trying to get postoperative
atheterizations whenever we use new techniques and generally
ave found that payers have been agreeable about paying for that
-week postoperative catheterization. Are there any data in the
iterature about graft patency with bivalirudin?
Dr Smedira. We do not have any patency angiography data
rom this study, but we do have Alan Merry’s study in New
ealand, in which he had angiograms on 60% to 70% of his
atients who had bivalirudin. In fact, using a TIMI-1, 2, 3 classi-
cation, he found that patients receiving bivalirudin had better
ow, more TIMI-3 flow in their grafts, than patients receiving
eparin. This is intriguing and suggests that the patency is better
ith bivalirudin. As you know quite well, from John Puskas’ data,
he patency in a lot of OPCABG studies has been very good, 90%
o 95% or better. However, we also have one study by Khan in The
ew England Journal of Medicine which shows that the patency of
he internal thoracic artery in the off-pump group is a good 8% to
0% lower than in the on-pump group and overall patency was
ignificantly less. This study has been criticized as coming from a
enter without a lot of experience with off-pump grafting. One
ossibility is that our study is a real-world phenomenon and
isplayed the type of patency one may see, regardless of which
rug is used for anticoagulation, in centers that are not doing 100%
f their cases off-pump.
Dr Joseph Cleveland (Denver, Colo). Given the observation
hat some of these thromboses were seen somewhat later, did you
xamine clopidogrel (Plavix) use in this group postoperatively? As
ou know, a lot of clopidogrel that is arbitrarily used for OPCAB
atients as there are reports in the literature regarding a potential
ncreased risk of thrombotic complications in this group of pa-
ients. Were there differences in the two groups with regard to
lopidogrel exposure postoperatively and could differential clopi-
ogrel exposure postoperatively account for some of these ob-
erved differences?
Dr Smedira. That is a great question. I don’t know the answer
o it, but that is something we can look into.
h 2006
